A recent report that ibrutinib resistance due to BTKCys481 mutations is driven by ERK1/2 activation with subsequent release of inflammatory cytokines including IL-6 and IL-10 provides further support for exploring upstream IRAK1 inhibition ABC-DLBCL and WM [168]. Here, IRAK1 is linked to diffuse large B-cell lymphoma.